Insulet

Traded on the St. Petersburg Stock Exchange
Insulet Corporation is an innovative medical device company based in Acton, Massachusetts. It was founded in 2000 with the mission of improving the lives of people with diabetes. With its Omnipod insulin control system, the company aims to expand the use of insulin pump therapy.
Insulet stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Insulet balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Insulet cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Insulet multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Insulet profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Insulet assets
Insulet cash flows

Insulet shares

TickerNameTypeNominal valueISINPrice
PODD:USInsulet Corp.Common share-US45784P1012$164.3
Insulet news
06.05.2022
Insulet's GAAP net income for 3 months of 2022 was $27.8 million. The company did not make a profit in the previous year. Revenue increased by 17.1% to $295.4 mln compared to $252.3 mln a year earlier.
24.02.2022
Insulet's GAAP net income for 2021 was $16.8 million, up 2.5 times from $6.8 million in the previous year. Revenue increased 21.6% to $1.099 billion from $0.904 billion a year earlier.
05.11.2021
Insulet's GAAP loss for 9M 2021 was $12.4 mln, against a profit of $23.9 mln in the previous year. Revenue increased 20.2% to $791.1 million from $658.3 million a year earlier.
06.08.2021
Insulet's GAAP loss for six months of 2021 was $25 million, compared to a profit of $12.3 million in the previous year. Revenue increased 21.5% to $515.5 mln, compared to $424.3 mln a year earlier.
General information
Company nameInsulet
SectorHealth Care / Health Care Equipment & Services / Health Care Equipment & Supplies / Health Care Supplies
Business address100 NAGOG PARK ACTON MA 01720 978-600-7000
Mailing address100 NAGOG PARK ACTON MA 01720
Websiteinvestor.insulet.com
Information disclosurewww.sec.gov